Can Fite Biopharma Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Can Fite Biopharma Ltd (CANF) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Can Fite Biopharma Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Scale: Can Fite Biopharma Ltd ranks #432 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Can Fite Biopharma Ltd accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CANF Sales vs. its Competitors, Q4 2025
Can Fite Biopharma Ltd generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -39.9% for Can Fite Biopharma Ltd. Can Fite Biopharma Ltd's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Can Fite Biopharma Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Can fite Biopharma Ltd | - | No | No | Yes |
| High-Confidence Competitors (20) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CANF Stock Performance relative to its Competitors
CANF Stock Performance relative to High-Confidence Competitors
CANF Stock Performance relative to Similar-Size Competitors
Can Fite Biopharma Ltd's Comment on Competition and Industry Peers
Can Fite Biopharma Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Regeneron | Named by the company | 85% |
| Amgen | Named by the company | 85% |
| BeOne Oncology | Named by the company | 85% |
| Eli Lilly | Named by the company | 85% |
| Intercept | Named by the company | 85% |
| Novavax | Named by the company | 85% |
| UCB | Named by the company | 85% |
| Abbvie | Named by the company | 85% |
| Bayer | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| Genfit | Named by the company | 85% |
| Moderna | Named by the company | 85% |
| Roche | Named by the company | 85% |
| AstraZenca | Named by the company | 85% |
| BioNTech | Named by the company | 85% |
| Exelixis | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
| Alumis | Named by the company | 85% |
| Beigene | Named by the company | 85% |
| Eisai | Named by the company | 85% |
| Gilead | Named by the company | 85% |
| Novartis | Named by the company | 85% |
| Takeda | Named by the company | 85% |
| AstraZeneca | Named by the company | 85% |
| Bristol-Myers | Named by the company | 85% |
| Galmed | Named by the company | 85% |
| Merck | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Can Fite Biopharma Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.